Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-09-22

Clinical Trial Update: Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma [Phase 2]

View source ↗

Summary

Phase 2 trial of tesevatinib monotherapy in recurrent glioblastoma has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • tesevatinib (tesevatinib)

Snippet

Sponsor: Kadmon Corporation, LLC | Conditions: Glioblastoma, Recurrent Glioblastoma | Phase 2 | Status: COMPLETED | Results posted: 2021-09-22